Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease

R Reilmann, S Tabrizi, B Leavitt, JC Stout, P Piccini, KE Anderson, A Feigin, M Hayden, M Grozinski-Wolff, E Eyal, S Papapetropoulos

Research output: Contribution to conferencePosterOtherpeer-review

Original languageEnglish
Pages246-247
Number of pages2
DOIs
Publication statusPublished - Jan 2016
EventNinth Annual Huntington Disease Clinical Research Symposium - Grant Hyatt , Tampa Bay, United States of America
Duration: 24 Oct 201524 Oct 2015
Conference number: 9th

Workshop

WorkshopNinth Annual Huntington Disease Clinical Research Symposium
CountryUnited States of America
CityTampa Bay
Period24/10/1524/10/15

Cite this

Reilmann, R., Tabrizi, S., Leavitt, B., Stout, JC., Piccini, P., Anderson, KE., ... Papapetropoulos, S. (2016). Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease. 246-247. Poster session presented at Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, United States of America. https://doi.org/10.1007/s13311-015-0390-6
Reilmann, R ; Tabrizi, S ; Leavitt, B ; Stout, JC ; Piccini, P ; Anderson, KE ; Feigin, A ; Hayden, M ; Grozinski-Wolff, M ; Eyal, E ; Papapetropoulos, S. / Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease. Poster session presented at Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, United States of America.2 p.
@conference{08ab183e692d475e91c1b5daed27b766,
title = "Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease",
author = "R Reilmann and S Tabrizi and B Leavitt and JC Stout and P Piccini and KE Anderson and A Feigin and M Hayden and M Grozinski-Wolff and E Eyal and S Papapetropoulos",
year = "2016",
month = "1",
doi = "10.1007/s13311-015-0390-6",
language = "English",
pages = "246--247",
note = "Ninth Annual Huntington Disease Clinical Research Symposium ; Conference date: 24-10-2015 Through 24-10-2015",

}

Reilmann, R, Tabrizi, S, Leavitt, B, Stout, JC, Piccini, P, Anderson, KE, Feigin, A, Hayden, M, Grozinski-Wolff, M, Eyal, E & Papapetropoulos, S 2016, 'Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease' Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, United States of America, 24/10/15 - 24/10/15, pp. 246-247. https://doi.org/10.1007/s13311-015-0390-6

Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease. / Reilmann, R; Tabrizi, S; Leavitt, B; Stout, JC; Piccini, P; Anderson, KE; Feigin, A; Hayden, M; Grozinski-Wolff, M; Eyal, E; Papapetropoulos, S.

2016. 246-247 Poster session presented at Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, United States of America.

Research output: Contribution to conferencePosterOtherpeer-review

TY - CONF

T1 - Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease

AU - Reilmann, R

AU - Tabrizi, S

AU - Leavitt, B

AU - Stout, JC

AU - Piccini, P

AU - Anderson, KE

AU - Feigin, A

AU - Hayden, M

AU - Grozinski-Wolff, M

AU - Eyal, E

AU - Papapetropoulos, S

PY - 2016/1

Y1 - 2016/1

U2 - 10.1007/s13311-015-0390-6

DO - 10.1007/s13311-015-0390-6

M3 - Poster

SP - 246

EP - 247

ER -